.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Julphar
Argus Health
Chinese Patent Office
Express Scripts
Harvard Business School
QuintilesIMS
Johnson and Johnson
UBS
Merck

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,853,231

« Back to Dashboard

Which drugs does patent 8,853,231 protect, and when does it expire?


Patent 8,853,231 protects XIFAXAN and is included in two NDAs. There has been one Paragraph IV challenge on Xifaxan.

This patent has eighty-one patent family members in thirty-five countries.

Summary for Patent: 8,853,231

Title:Pharmaceutical compositions comprising polymorphic forms .alpha., .beta., and .gamma. of rifaximin
Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin .alpha. and rifaximin .beta., and a poorly crystalline form referred to as rifaximin .gamma., useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
Inventor(s): Viscomi; Giuseppe Claudio (Bologna, IT), Campana; Manuela (Bologna, IT), Braga; Dario (Bologna, IT), Confortini; Donatella (Bologna, IT), Cannata; Vincenzo (Bologna, IT), Righi; Paolo (Bologna, IT), Rosini; Goffredo (Bologna, IT)
Assignee: Alfa Wassermann S.p.A. (Alanno (PE), IT)
Application Number:13/679,602
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Salix Pharms
XIFAXAN
rifaximin
TABLET;ORAL022554-001Mar 24, 2010RXYesYes► Subscribe► SubscribeY
Salix Pharms
XIFAXAN
rifaximin
TABLET;ORAL021361-001May 25, 2004RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,853,231

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,158,644Pharmaceutical compositions comprising polymorphic forms .alpha., .beta., and .gamma. of rifaximin► Subscribe
7,045,620Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations► Subscribe
7,906,542Pharmaceutical compositions comprising polymorphic forms .alpha., .beta., and .gamma. of rifaximin► Subscribe
8,404,704Use of polymorphic forms of rifaximin for medical preparations► Subscribe
7,923,553Processes for the production of polymorphic forms of rifaximin► Subscribe
7,902,206Polymorphic forms .alpha., .beta. and .gamma. of rifaximin► Subscribe
8,158,781Polymorphic forms .alpha., .beta. and .gamma. of rifaximin► Subscribe
7,612,199Polymorphic forms .alpha., .beta., and .gamma. of rifaximin► Subscribe
7,915,275Use of polymorphic forms of rifaximin for medical preparations► Subscribe
8,835,452Polymorphic forms .alpha., .beta. and .gamma. of rifaximin► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,853,231

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Serbia54569► Subscribe
Serbia20150291► Subscribe
TaiwanI285107► Subscribe
Taiwan200515913► Subscribe
TunisiaSN06069► Subscribe
Serbia20150292► Subscribe
Serbia54571► Subscribe
Serbia54568► Subscribe
Portugal1676848► Subscribe
Portugal1676847► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
QuintilesIMS
Healthtrust
Express Scripts
US Army
Argus Health
Mallinckrodt
Boehringer Ingelheim
Harvard Business School
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot